HeartSciences (HSCS) Projected to Announce Earnings on Thursday

HeartSciences (NASDAQ:HSCS) is expected to be posting its Q4 2026 results before the market opens on Thursday, July 23rd. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $0.05 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Friday, July 31, 2026 at 4:00 PM ET.

HeartSciences Stock Performance

Shares of HSCS stock opened at $2.46 on Wednesday. The firm has a market capitalization of $7.82 million, a price-to-earnings ratio of -0.50 and a beta of 1.78. The company has a current ratio of 1.19, a quick ratio of 1.04 and a debt-to-equity ratio of 0.16. The business’s 50-day moving average price is $2.24 and its 200-day moving average price is $2.51. HeartSciences has a 12 month low of $1.63 and a 12 month high of $4.30.

Hedge Funds Weigh In On HeartSciences

A hedge fund recently bought a new position in HeartSciences stock. Geode Capital Management LLC acquired a new position in HeartSciences Inc. (NASDAQ:HSCS) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned 0.51% of HeartSciences at the end of the most recent reporting period. 17.24% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HSCS has been the subject of a number of research reports. Ascendiant Capital Markets dropped their price objective on shares of HeartSciences from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, March 24th. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, HeartSciences has an average rating of “Hold” and an average price target of $8.00.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.